xinbang phar.(SZ:002390) Xin Lang Cai Jing·2025-10-22 06:17Group 1 - The core viewpoint of the news is that Xinfang Pharmaceutical's stock price increased by 5.7% to 4.08 CNY per share, with a trading volume of 261 million CNY and a market capitalization of 7.931 billion CNY as of October 22 [1] - Xinfang Pharmaceutical, established on January 27, 1995, and listed on April 16, 2010, primarily engages in the research, production, and sales of natural plant-based traditional Chinese medicine and biopharmaceuticals [1] - The company's revenue composition includes 75.12% from pharmaceutical distribution, 27.80% from medical services, 17.27% from pharmaceutical manufacturing, and 0.03% from other industries [1] Group 2 - Among the top shareholders of Xinfang Pharmaceutical, a fund under Southern Fund increased its holdings in the Southern CSI 1000 ETF (512100) by 2.1141 million shares in the second quarter, now holding 10.8419 million shares, which is 0.59% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 64.953 billion CNY, achieving a year-to-date return of 24.69% and a one-year return of 26.71% [2] - The fund manager of Southern CSI 1000 ETF is Cui Lei, who has been in the position for 6 years and 351 days, with a total asset scale of 94.976 billion CNY [3]